Dow Jones Up 0.31% to 46,350.65 Points

The major averages were mixed near noon, with the Dow and S&P 500 inching higher following yestereday's gains. The bounce yesterday was driven by headlines suggesting a de-escalation with Iran, but that narrative is already fraying. Oil has turned higher again, climbing back above $90 for the WTI benchmark as optimism fades and the reality of disrupted supply through the Strait of Hormuz reasserts itself.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Estee Lauderconfirmed it iswith Puig BrandsSmithfield Foodsreportedand provided FY26 revenue guidanceNetgearsurged following reports that the FCC hasSumitomo Mitsuiis considering a potential takeover of Jefferies,Ares Managementsaid it isin the Ares Strategic Income fund2. WALL STREET CALLS:UBSJFrogto Buy after 30% AI-driven selloffCoreWeaveat Buy at BofACitiRalph Laurento Buy on post-selloff opportunityJPMorganXencoron a lack of "needle-moving" catalystsUltragenyxto Neutral from Buy at Goldman Sachs3. AROUND THE WEB:Microsoft (MSFT) to rent data center project in Texas dropped by Oracle, Bloomberg saysSouth Korean AI startup Upstage is in talks to acquire 10K AMDMI355 chips, in a bid to "diversify to other chips" as "we have a lot of Nvidiachips," Bloomberg reportsPalantirhas been awarded a three-month contract by the UK's Financial Conduct Authority to analyze sensitive internal data in an effort to combat financial crime, sparking concerns about the U.S. firm's expanding role in the British state, The Guardian saysNintendohas cut back on the production of the Switch 2 after lower-than-expected demand for the $450 gaming console during the year-end holiday season, Bloomberg reportsGooglehas signed agreements with five U.S. electric utilities to curtail its electricity use during peak demand, Reuters says4. MOVERS:Applied Optoelectronicsincreases after receiving afrom a hyperscale customerSM Energygains after Truistof the stock with a Buy ratingHesaislips afterand providing guidance for Q1ImmunityBiolower after the FDA sent arelated to the promotion of AnktivaOcugenfalls after announcingfrom its ArMaDa trial of OCU4105. EARNINGS/GUIDANCE:Core & Mainand provided guidance for Q1 and FY26, with CEO Mark Witkowski commenting, "Fiscal 2025 marked our 16th consecutive year of sales growth"Concentrix, with EPS missing consensusAchieve Life Sciences, with EPS in-line with consensusCore LaboratoriesNeurogene, with EPS higher year-over-yearINDEXES:Near midday, the Dow was up 0.31%, or 142.18, to 46,350.65, the Nasdaq was down 0.27%, or 59.83, to 21,886.93, and the S&P 500 was up 0.13%, or 8.57, to 6,589.57.